Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2135002 | 1.00 | ARG1 (0.38) | ARG1SLC1A2MAPK1MEN1BLM | |
| SCHEMBL2134995 | 1.00 | ARG1 (0.38) | ARG1SLC1A2MAPK1MEN1BLM | |
| SCHEMBL9658075 | 0.77 | ARG1 (0.47) | ARG1SLC1A2MEN1BLMKMT2A | |
| SCHEMBL3843714 | 0.75 | USP2 (0.33) | MAPK1 | |
| SCHEMBL3712795 | 0.74 | ARG1 (0.41) | ARG1 | |
| SCHEMBL17756064 | 0.72 | SLC1A2 (0.58) | ARG1SLC1A2MEN1BLMKMT2A | |
| SCHEMBL3427826 | 0.72 | SLC1A2 (0.58) | ARG1SLC1A2MEN1BLMKMT2A | |
| SCHEMBL5728913 | 0.72 | MAPK1 (0.37) | SLC1A2MAPK1 | |
| SCHEMBL9723724 | 0.70 | ARG1 (0.36) | ARG1 | |
| SCHEMBL20599827 | 0.70 | BTK (0.38) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | UROD, UMPS, SLC14A1 | ARG1 73/4885SLC1A2 3750/4885MAPK1 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.